PDF下载 ( 2025 KB)
Clinical features of hyperlipidemic acute pancreatitis and their association with lipid metabolism
-
摘要: 目的探讨高脂血症性急性胰腺炎（HLAP）患者的临床特征,以及脂代谢谱与HLAP的关系。方法选取2017年9月-2019年9月昆明医科大学第二附属医院消化内科收治的61例HLAP患者（HLAP组）与同期77例非高脂血症性急性胰腺炎患者（NONHLAP组）。分析2组患者的临床特点,包括基线资料、实验室指标、病情分级、合并症、严重程度评分等。符合正态分布的计量资料2组间比较采用t检验;不满足正态分布的计量资料2组间比较采用Mann-Whitney U检验。计数资料2组间比较采用χ2检验。采用多因素二分类logistic回归分析HLAP的独立危险因素,Z检验比较受试者工作特征曲线下面积（AUC）。结果 2组间年龄（t=-6. 125）,BMI（t=4. 125）,合并感染（χ2=4. 364）、脂肪肝（χ2=50. 567）、糖尿病（χ2=28. 408）,hs-CRP（Z=-2. 456）,WBC（t=2. 652）,中性粒细胞（t=2. 232）,淋巴细胞（Z=-2. 339）,D二聚体（Z=-8. 6...
-
关键词:
- 高脂血症性急性胰腺炎 /
- 脂代谢障碍 /
- 载脂蛋白类 /
- 脂蛋白类
Abstract: Objective To investigate the clinical features of patients with hyperlipidemic acute pancreatitis( HLAP) and the association between lipid metabolism profile and HLAP. Methods A total of 61 patients with HLAP who were treated in Department of Gastroenterology,The Second Affiliated Hospital of Kunming Medical University,from September 2017 to September 2019 were enrolled as HLAP group,and77 patients with non-hyperlipidemic acute pancreatitis were as non-HLAP group. The clinical features of the two groups were analyzed,including baseline data,laboratory markers,disease grade,comorbidities,and severity score. The t-test was used for comparison of normally distributed continuous data between groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. The chi-square test was used to for comparison of categorical data between groups. A multivariate binary logistic regression analysis was used to investigate the independent risk factors for HLAP,and the Z test was used for comparison of the area under the ROC curve( AUC). Results There were significant differences between the two groups in age( t =-6. 125,P < 0. 05),body mass index( t = 4. 125,P < 0. 05),infection( χ2= 4. 364,P < 0. 05),fatty liver disease( χ2= 50. 567,P < 0. 05),diabetes( χ2=28. 408,P < 0. 05),high-sensitivity C-reactive protein( Z =-2. 456,P < 0. 05),white blood cell count( t = 2. 652,P < 0. 05),neutrophils( t = 2. 232,P < 0. 05),lymphocytes( Z =-2. 339,P < 0. 05),D-dimer( Z =-8. 601,P < 0. 05),fasting blood glucose( Z =-4. 416,P < 0. 05),uric acid( t = 4. 644,P < 0. 05),total cholesterol( Z =-8. 937,P < 0. 05),triglyceride( Z =-8. 87,P <0. 05),low-density lipoprotein cholesterol( Z =-7. 972,P < 0. 05),non-high-density lipoprotein( Z =-9. 085,P < 0. 05),apolipoprotein B( Z =-3. 244,P < 0. 05),systemic inflammatory response syndrome score( Z =-2. 817,P < 0. 05),and Modified Early Warning Score( Z =-2. 226,P < 0. 05). Triglyceride( odds ratio [OR]= 0. 675,95% confidence interval [CI]: 0. 484-0. 943,P =0. 021) and non-high-density lipoprotein( OR = 0. 320,95% CI: 0. 164-0. 624,P = 0. 001) were independent risk factors for HLAP.Non-high-density lipoprotein( AUC = 0. 951,sensitivity = 100%,specificity = 88. 31%,95% CI: 0. 901-0. 981,SE = 0. 020,Youden index = 0. 883) and triglyceride( AUC = 0. 940,sensitivity = 95. 08%,specificity = 81. 82%,95% CI: 0. 887-0. 974,SE = 0. 018,Youden index = 0. 769) had high diagnostic efficiency. Non-high-density lipoprotein with a cut-off value of > 4. 55 mmol/L had the highest diagnostic value. Conclusion HLAP often occurs in the population with metabolic syndrome,with a younger age of onset and more severe inflammatory response. Non-high-density lipoprotein has a high value in the diagnosis of HLAP,which provides a new idea for guiding clinical treatment. -
[1] HUANG W,WINDSOR JA. Fulminant or early severe acute pancreatitis is overlooked by classifications of severity[J].Crit Care Med,2017,45(7):e744-e745. [2] HUANG YX,JIA L,JIANG SM,et al. Incidence and clinical features of hyperlipidemic acute pancreatitis from Guangdong,China:A retrospective multicenter study[J]. Pancreas,2014,43(4):548-552. [3] ZHANG N,ZHANG HY,GUO XH,et al. Meta-analysis of the characteristics of the etiology of acute pancreatitis in China in the past ten years[J/CD]. Chin J Digest Med Imageol(Electronic Edition),2016,6(2):71-75(in Chinese)．张娜，张海燕，郭晓红，等．中国近十年急性胰腺炎病因变化特点的Meta分析[J/CD]．中华消化病与影像杂志(电子版)，2016,6(2):71-75. [4] WANG XP,LI ZS,YUAN YZ,et al. Chinese guidelines for the diagnosis and treatment of acute pancreatitis(2013,Shanghai)[J]. J Clin Hepatol,2013,29(9):656-660.(in Chinese)王兴鹏，李兆申，袁耀宗，等．中国急性胰腺炎诊治指南(2013年，上海)[J]．临床肝胆病杂志，2013,29(9):656-660. [5] YEH JH,CHEN JH,CHIU HC. Plasmapheresis for hyperlipidemic pancreatitis[J]. J Clin Apher,2003,18(4):181-185. [6] MA JC,BAO ZJ. Research progress on the pathogenesis of hyperlipidemic acute pancreatitis[J]. Int J Dig Dis,2017,37(1):24-27.(in Chinese)马江辰，保志军．高脂血症性急性胰腺炎发病机制的研究进展[J]．国际消化病杂志，2017,37(1):24-27. [7] PACKARD CJ. Determinants of achieved LDL cholesterol and“Non-HDL”cholesterol in the management of dyslipidemias[J]. Curr Cardiol Rep,2018,20(8):60. [8] RAMJEE V,SPERLING LS,JACOBSON TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification:Do the math[J]. J Am Coll Cardiol,2011,58(5):457-463. [9] MASSON W,LOBO M,SINIAWSKI D,et al. Impact of lipidlowering therapy on mortality according to the baseline NonHDL cholesterol level:A meta-analysis[J]. High Blood Press Cardiovasc Prev,2019,26(4):263-272. [10] YADAV D,PITCHUMONI CS. Issues in hyperlipidemic pancreatitis[J]. J Clin Gastroenterol,2003,36(1):54-62. [11] SUDHOP T. Inhibition of intestinal cholesterol absorption by ezetimibe in humans[J]. Circulation,2003,106(15):1943-1948. [12] CAO X,WANG HM,DU H,et al. Early predictors of hyperlipidemic acute pancreatitis[J]. Exp Ther Med,2018,16(5):4232-4238. [13] WANG BB,LIAO SY,MA J,et al. Analysis of clinical characteristics of acute pancreatitis with different etiology[J]. J Clin Hepatol,2018,34(1):147-151.(in Chinese)王蓓蓓，廖山婴，马娟，等．不同病因急性胰腺炎的临床特点分析[J]．临床肝胆病杂志，2018,34(1):147-151. [14] LI HQ,LIU W,TANG J,et al. Evaluation value of triglyceride,C-reactive protein and procalcitonin on the severity and prognosis of hyperlipidemic acute pancreatitis[J]. Clin J Med Offic,2019,47(9):923-925.(in Chinese)历海清，刘卫，唐郡，等．甘油三酯、C反应蛋白、降钙素原对高脂血症性急性胰腺炎病情严重程度及预后评估价值[J]．临床军医杂志，2019,47(9):923-925. 期刊类型引用(28)
1. 袁雅丹，蒋淑君，张彦亮. 温胆汤及其加减方治疗代谢相关性疾病的研究进展. 长春中医药大学学报. 2025(03): 328-333 . 
百度学术2. 杜学芳，马尚超，张利利，张超群，姬娟娟，张彩凤. 低分子肝素联合苯扎贝特治疗高脂血症性急性胰腺炎的效果. 河南医学研究. 2024(17): 3215-3219 . 百度学术3. 黄睿，廖静，张怀蓉，邵艳霞，王钰姝，蒋春梅，肖伟，聂旭彪，曾冬梅. 高脂血症性和胆源性重症急性胰腺炎临床特点及预后对比分析. 检验医学与临床. 2024(18): 2633-2636 . 百度学术4. 奇丽娜，陈平. 高脂血症性急性胰腺炎反复发作的病因及防治策略. 临床肝胆病杂志. 2024(10): 2109-2115 . 
本站查看5. 杨卫生，丁元军，吴燕，梁秀婷，叶文冲，方年富. 大黄芒硝汤联合低分子肝素对高甘油三酯血症性急性胰腺炎患者C反应蛋白、甘油三酯及凝血功能的影响. 药品评价. 2024(07): 907-910 . 百度学术6. 孙坤举，孟婧，修珊珊，王新伟，孟晓敏，李艺，陈家洛，胡燃. 回顾性研究降脂清胰汤治疗高脂血症性急性胰腺炎的临床疗效. 中国中医急症. 2024(11): 1985-1988 . 百度学术7. 方聪，盛锦义. 低分子量肝素钙联合胰岛素治疗对高脂血症性胰腺炎患者生化指标和炎性因子的影响. 药品评价. 2024(10): 1260-1263 . 百度学术8. 张涛，邹萍，赵琦. 高脂血症胰腺炎患者血清血管紧张素转化酶2与巨噬细胞移动抑制因子水平检测及临床意义. 河北医科大学学报. 2023(06): 724-728 . 百度学术9. 张艳青，郭安兵，彭利军. 血脂康胶囊联合非诺贝特胶囊治疗高脂血症性胰腺炎的疗效观察. 临床和实验医学杂志. 2023(17): 1809-1813 . 百度学术10. 颜博，付泓锐，舒义雄. 高脂血症性急性胰腺炎复发危险因素的研究. 胃肠病学和肝病学杂志. 2023(09): 1029-1033 . 百度学术11. 王建强，李迎敏，杨小庆. 高脂血症性胰腺炎患者血浆中Ca~(2+)、C-反应蛋白及纤维蛋白原水平变化及其临床意义. 川北医学院学报. 2023(12): 1693-1696 . 百度学术12. 胡业顺，杨晓丽，王启志，密亚琦，胡晓波，张飞虎. 大承气汤化裁灌肠联合西医治疗高脂血症性急性胰腺炎疗效分析. 中国中医急症. 2023(12): 2171-2174 . 百度学术13. 段理华，陈碧兰，曹红霞. 阿托伐他汀联合温胆汤治疗高脂血症的临床疗效. 深圳中西医结合杂志. 2023(19): 43-45 . 百度学术14. 张璐，彭时成，姜娇，雷加明，倪培萍，吕沐瀚. 非高密度脂蛋白胆固醇与高脂血症性急性胰腺炎预后的相关性分析. 胃肠病学和肝病学杂志. 2022(04): 444-448 . 百度学术15. 巫泓生，马克强，廖碧玲，嵇腾飞，黄健斌，曹天生. 无创心排量联合中心静脉血氧饱和度监测对高脂血症性重症胰腺炎早期目标导向性液体复苏的指导作用. 临床肝胆病杂志. 2022(07): 1602-1607 . 本站查看16. 陈锋，林国良. 低分子肝素与普通肝素治疗高脂血症性胰腺炎的疗效对比. 北方药学. 2022(09): 117-119+128 . 百度学术17. 侯静琳. 高脂血症性急性胰腺炎及非高脂血症性急性胰腺炎的临床特点及CRP对其严重程度的评估价值. 名医. 2022(18): 21-23 . 百度学术18. 侯丽君，唐艳. 高脂血症性急性胰腺炎患者hs-CRP及脂代谢变化相关性研究. 甘肃科技纵横. 2022(12): 82-85 . 百度学术19. 黄俊. 急性胰腺炎患者血脂代谢特点和CRP水平与病情进展的关系分析. 现代诊断与治疗. 2022(23): 3559-3562 . 百度学术20. 叶思婷，顾忠民，江贤威，陈超. 高脂血症性重症胰腺炎与胆源性急性重症胰腺炎的临床特点比较. 中外医疗. 2022(33): 14-17 . 百度学术21. 魏国峰，蔡兆辉，李玉，张旗，陈良，陈辉，李海山. 轻中度急性胰腺炎合并代谢综合征的临床特点及短期复发影响因素研究. 肝胆外科杂志. 2022(06): 449-453 . 百度学术22. 刘国雄，匡桥贵，喻欣荷，刘访，王宇，俞洋，陈杨. 加味大承气汤治疗湿热蕴结型高脂血症性急性胰腺炎的疗效及作用机制. 中国实验方剂学杂志. 2021(05): 91-97 . 百度学术23. 孟露，郭华，高剑波. 急性胰腺炎合并脂肪肝CT特征性分析. 临床放射学杂志. 2021(03): 495-498 . 百度学术24. 陈丽芳，余华军，黄颖宝，孙文娜，孙洪伟，金尹，吴恩福. CT评估的脂肪肝与高脂血症性急性胰腺炎严重程度的相关性. 温州医科大学学报. 2021(07): 554-559 . 百度学术25. 盛锦义，姜景平，汪福昌. 低分子量肝素钠联合乌司他丁治疗高脂血症性胰腺炎的效果观察. 中国医学创新. 2021(26): 70-73 . 百度学术26. 黄治家，吕毅. 低分子肝素联合前列地尔注射液治疗高脂血症性急性胰腺炎患者的临床研究. 中国临床药理学杂志. 2021(21): 2870-2874 . 百度学术27. 黄莹，苗雨，林晚，刘昊，张飞雄，阮继刚. 急性复发性胰腺炎合并代谢综合征的临床特点及预后分析. 宁夏医学杂志. 2021(11): 968-971 . 百度学术28. 王渊博，吴海燕，郑长虹，张怡冰. 瑞舒伐他汀联合免疫三氧治疗Ⅱ型糖尿病合并高脂血症患者疗效研究. 创伤与急危重病医学. 2020(06): 417-420 . 百度学术其他类型引用(6)
-
百度学术
下载:
